Function Health just raised $298 million in Series B at a $2.5 billion valuation — and simultaneously acquired GetLabs (at-home blood draw service) and SuppCo (supplement startup). The ambition: build an integrated health testing + personalized supplement platform. It's one of the most significant healthtech raises of 2026, and it signals where consumer health is heading.
Key Takeaways
- Function raises $298M in Series B — $2.5B valuation
- Simultaneous acquisitions: GetLabs (at-home diagnostics) + SuppCo (supplements)
- Model: 60+ biomarkers analyzed, AI interpretation, personalized supplements on subscription
- Trend: health moving from reactive to predictive — test, optimize, prevent
What Function is building
Function's model is based on a simple observation: traditional supplementation is blind. People take vitamin D without knowing if their levels are low, creatine without knowing their recovery profile, omega-3s without measuring their index. Function wants to flip that: test first (60+ biomarkers via at-home blood draw through GetLabs), analyze with AI, then recommend exactly the needed supplements and deliver them via subscription.
The SuppCo acquisition — a startup that had built an evidence-based supplement marketplace — completes the stack. Function now has the collection infrastructure (GetLabs), the analysis engine (proprietary AI), and supplement fulfillment (SuppCo).
What it says about the wellness market
Function's $2.5B valuation signals investor appetite for consumer-accessible "personalized medicine." This isn't hospital curative medicine — it's preventive and optimization-focused health for consumers who want data on their own bodies and interventions calibrated to that data.
The at-home diagnostics market is growing at 15%+ annually. Function is betting that by combining testing and supplements in a single subscription, it can capture a significant share while creating strong retention (once you have your baseline data, you want to recheck it in 3 months).
Key takeaways
- Function: $298M raised, $2.5B valuation — one of the biggest healthtech rounds of 2026.
- The vertically integrated model (diagnostics + AI + supplements) directly addresses today's blind supplementation problem.
- Diagnostic-supplement convergence is a structural trend: consumers want to know why they're taking what they're taking.
- For supplement brands: data-driven positioning is becoming a central differentiator vs. brand-only competitors.